The study will evaluate average 24-hr sodium excretion during dapagliflozin treatment in patients with Type 2 Diabetes Mellitus with preserved or impaired renal function or non-diabetics with impaired renal function.

Trial Identifier: D1690C00049
Sponsor: AstraZeneca
NCTID:: NCT03152084
Start Date: July 2017
Primary Completion Date: March 2020
Study Completion Date: March 2020
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Dutch Translation
Swedish Translation

Trial Locations

Country Location
Netherlands Almelo, Netherlands, 7609 PP
Netherlands Amsterdam, Netherlands, 1081 HV
Sweden Örebro, Sweden, 70185
Sweden Stockholm, Sweden, 14186